Clinical trials
Moderately to Severely Active Ulcerative Colitis clinical trials
Below are recruiting moderately to severely active ulcerative colitis clinical trials, each written for real people, not researchers. We’re tracking 108 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07196748RecruitingPhase 3
Icotrokinra for adults and teens with moderate to severe ulcerative colitis
This trial tests a new oral medication, icotrokinra, for people with moderately to severely active ulcerative colitis. It may be an option if you have not responded well enough to standard treatments or newer advanced therapies.
Chandler, ArizonaAges 12 years+ - NCT07577856RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe ulcerative colitis
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
Anaheim, CaliforniaAges 18 years+ - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Dothan, AlabamaAges 18–75 - NCT06979336RecruitingPhase 2
New drug for moderate to severe UC
This study tests an experimental drug called RO7837195 for people with moderate to severe ulcerative colitis (UC) who haven't gotten enough help from other treatments. It aims to see if this new drug can reduce inflammation and improve symptoms.
Lancaster, CaliforniaAges 18 years+ - NCT07786389Enrolling by invitationPhase 1/Phase 2
Seaweed supplement for ulcerative colitis inflammation
This study tests whether a supplement made from seaweed (fucoidan) can help reduce gut inflammation in people with mild to moderate ulcerative colitis. If you join, you'll take the supplement and have your symptoms and blood levels checked.
Lahore, Punjab ProvinceAges 18–64 - NCT07389824Recruiting
Acupuncture plus mesalazine for ulcerative colitis
This study tests whether adding acupuncture (using small intradermal needles) to the standard medication mesalazine improves outcomes for people with mild-to-moderate ulcerative colitis. Participants receive 12 acupuncture sessions and undergo two colonoscopies to assess the treatment's effect.
Wuhan, HubeiAges 18–75 - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Canoga Park, CaliforniaAges 18–75 - NCT07470879RecruitingPhase 2
Etrasimod for Children with Ulcerative Colitis
This trial tests if the medicine etrasimod can help children with moderate to severe ulcerative colitis. You may still be able to join even if you are already taking other treatments for your condition.
New York, New YorkAges 2–11 - NCT06937086RecruitingPhase 3
Mirikizumab plus tirzepatide for UC with obesity
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
Dothan, AlabamaAges 18–70 - NCT07415044RecruitingPhase 2
Study of LY4268989 for moderate to severe ulcerative colitis
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 18–80 - NCT07665723RecruitingPhase 1
Study of afimkibart and other medicines in ulcerative colitis
This study looks at how afimkibart affects the way your body processes certain other medicines. It is for people with moderate to severe ulcerative colitis and helps researchers understand how to use this treatment safely.
Chula Vista, CaliforniaAges 18–60 - NCT06819878RecruitingPhase 3
Afimkibart for moderate to severe Crohn's disease
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
Dothan, AlabamaAges 16–80 - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Peoria, ArizonaAges 16–80 - NCT07726888Recruiting
Guselkumab for moderate-to-severe ulcerative colitis
This study tests a drug called Guselkumab (already approved for other conditions) for treating moderate to severe ulcerative colitis. It aims to see how safe and effective the drug is in real-world patients who have not had success with other treatments.
Wenzhou, ZhejiangAges 18 years+ - NCT07686081RecruitingPhase 3
Testing ponesimod for moderate to severe ulcerative colitis
This trial tests an oral medication called ponesimod for people with ulcerative colitis that hasn't responded well to other treatments. It aims to see if ponesimod can reduce inflammation and improve symptoms.
Chula Vista, CaliforniaAges 18–75 - NCT07463183RecruitingPhase 2
Study of MK-8690 for moderate to severe ulcerative colitis
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
Anaheim, CaliforniaAges 18–75 - NCT07136116Recruiting
Study of risankizumab for moderate to severe ulcerative colitis in Japan
This study looks at how well risankizumab (an injected medicine) works for people with moderate to severe ulcerative colitis. It tracks your symptoms using a mobile app to see if the drug helps control the disease.
Nagakute, Aichi-kenAges 15 years+ - NCT07158242RecruitingPhase 3
Study of afimkibart for children with active ulcerative colitis
This study tests a new drug called afimkibart in children with moderate to severe ulcerative colitis who haven't responded well to other treatments. It aims to see how well the drug works and if it's safe for children.
Aurora, ColoradoAges 2–17 - NCT05867329RecruitingPhase 4
Comparing treatments for severe ulcerative colitis flare-ups
This study compares different sequences of medicines for treating severe ulcerative colitis flares in the hospital. It aims to find the best way to get your symptoms under control and help you feel better faster.
Ann Arbor, MichiganAges 18–75 - NCT07298421RecruitingPhase 3
Testing afimkibart for children with Crohn's disease
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
New York, New YorkAges 2–17 - NCT06588855RecruitingPhase 3
Study of afimkibart for moderate to severe ulcerative colitis
This trial is testing a new medication called afimkibart (RO7790121) for people with moderate to severe ulcerative colitis. It aims to see if this treatment can help reduce inflammation and improve symptoms in people who haven't had success with other therapies.
Dothan, AlabamaAges 16–80 - NCT06819891RecruitingPhase 3
Study of afimkibart for active Crohn's disease
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
Dothan, AlabamaAges 16–80 - NCT07258771RecruitingPhase 4
Upadacitinib plus steroids vs steroids alone for severe ulcerative colitis
This trial tests if adding upadacitinib (a pill) to standard steroid treatment helps people with a severe flare of ulcerative colitis feel better faster. You may qualify if you are having frequent bloody stools and signs of serious inflammation, and you haven't tried upadacitinib before.
Ann Arbor, MichiganAges 18–75 - NCT07229950RecruitingPhase 2
Experimental tablet for moderate to severe Ulcerative Colitis
This trial tests an experimental tablet, HRS-7085, for people with moderate to severe Ulcerative Colitis who haven't gotten enough help from standard treatments. The goal is to see if the drug can reduce inflammation and improve symptoms.
Chengdu, SichuanAges 18–75
Hear when a new Moderately to Severely Active Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderately to severely active ulcerative colitis?
- Yes. Clin2 currently lists 108 recruiting moderately to severely active ulcerative colitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderately to severely active ulcerative colitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderately to severely active ulcerative colitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.